Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

被引:0
|
作者
Li, Qingsong [1 ,2 ,3 ]
Liang, Na [1 ,2 ,3 ]
Ouyang, Weiwei [1 ,2 ,3 ]
Su, Shengfa [1 ,2 ,3 ]
Ma, Zhu [1 ,2 ]
Geng, Yichao [1 ,2 ,3 ]
Hu, Yinxiang [1 ,2 ,3 ]
Li, Huiqin [1 ,2 ]
Lu, Bing [1 ,2 ,3 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Clin Med Coll, Teaching & Res Dept Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
关键词
Time; Non-small cell lung cancer (NSCLC); EGFR-TKIs; Primary tumor radiotherapy; Overall survival; TYROSINE KINASE INHIBITORS; OPEN-LABEL; PHASE-III; ADENOCARCINOMA HISTOLOGY; CONCURRENT CHEMOTHERAPY; MAINTENANCE THERAPY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; RADIATION-THERAPY; GEFITINIB;
D O I
10.1186/s12885-024-12826-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. Patients and methods In total, 238 patients with EGFR-TKIs and OS >= 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it. The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 - 30(<30 days), R30 - PD(>= 30 days and disease stable), and R-PD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. Results The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3-33.7) for the R group and 22 months(95% CI: 20.4-23.6) for the D group (chi(2) = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS. Among the four groups, The R30 - PD appeared to have the best OS (D, chi(2) = 19.307, p<0.001;R0 - 30, chi(2) = 11.687, p = 0.01; R-PD, chi(2) = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 - PD group had a significant long-term OS. The incidence of radiation pneumonitis >= grade 2 was17.3%(n = 19)and radiation esophagitis >= grade 2 was observed in 32 patients(29.1%). Conclusions Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 - PD)of primary tumour radiotherapy may be the best choice. Premature radiotherapy(R0 - 30) and radiotherapy after disease progression (R-PD)may not be reasonable for long-term OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
    Zhao, Dan
    Chen, Xuejing
    Qin, Na
    Su, Dan
    Zhou, Lijuan
    Zhang, Quan
    Li, Xi
    Zhang, Xinyong
    Jin, Mulan
    Wang, Jinghui
    SCIENTIFIC REPORTS, 2017, 7
  • [12] Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
    Shi, Xiaoshun
    Dong, Xiaoying
    Zhai, Jianxue
    Liu, Xiguang
    Lu, Di
    Ni, Zhen
    Wu, Hua
    Cai, Kaican
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [13] The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    THORACIC CANCER, 2023, 14 (04) : 348 - 356
  • [14] Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
    Wang, Xiaohong
    Liu, Yonggang
    Meng, Zhiying
    Wu, Yun
    Wang, Shubin
    Jin, Gaowa
    Qin, Yingchun
    Wang, Fengyun
    Wang, Jing
    Zhou, Haifei
    Su, Xiaoxing
    Fu, Xiuhua
    Wang, Xiaolan
    Shi, Xiaoyu
    Wen, Zhenping
    Jia, Xiaoqiong
    Qin, Qiong
    Gao, Yongqiang
    Guo, Weidong
    Lu, Shun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [15] Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
    Cheng, Ningning
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Chen, Xiaoxia
    Cai, Weijing
    Zhao, Mingchuan
    Zhang, Yishi
    Li, Jiayu
    Wang, Qi
    Zhou, Caicun
    ONCOLOGY REPORTS, 2015, 33 (02) : 833 - 839
  • [16] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
    Holleman, Marscha S.
    Al, Maiwenn J.
    Zaim, Remziye
    Groen, Harry J. M.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01) : 153 - 164
  • [17] Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry
    Yang, Shaoyu
    Chen, Xueqin
    Pan, Yuelong
    Yu, Jiekai
    Li, Xin
    Ma, Shenglin
    MOLECULAR MEDICINE REPORTS, 2016, 14 (05) : 4823 - 4829
  • [18] Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer
    Takemura, Yoshizumi
    Chihara, Yusuke
    Morimoto, Yoshie
    Tanimura, Keiko
    Imabayashi, Tatsuya
    Seko, Yurie
    Kaneko, Yoshiko
    Date, Koji
    Ueda, Mikio
    Arimoto, Taichiro
    Iwasaki, Yoshinobu
    Takayama, Koichi
    ANTICANCER RESEARCH, 2018, 38 (04) : 2385 - 2390
  • [19] A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
    Cheng, Hua
    Li, Xiao-Jian
    Wang, Xiao-Jin
    Chen, Zuo-Wen
    Wang, Rui-Qi
    Zhong, Hong-Cheng
    Wu, Tian-Chi
    Cao, Qing-Dong
    LUNG CANCER, 2019, 137 : 7 - 13
  • [20] Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
    Takeuchi, Akira
    Oguri, Tetsuya
    Sone, Kazuki
    Ito, Keima
    Kitamura, Yuki
    Inoue, Yoshitsugu
    Asano, Takamitsu
    Fukuda, Satoshi
    Kanemitsu, Yoshihiro
    Takakuwa, Osamu
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Niimi, Akio
    ANTICANCER RESEARCH, 2017, 37 (10) : 5771 - 5776